Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir + Lamivudine vs DTG + TDF/FTC in HIV-1
NCT04549467Phase 4Completed
- Sponsor
- Fundación IDEAA
- Start
- Nov 2020
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in human immunodeficiency virus type 1 infection (HIV-1) comparing Dolutegravir + lamivudine with Dolutegravir + emtricitabine/tenofovir (2 arms). Primary endpoint: Virologic Efficacy (VL < 50 c/ml) at 48 weeks. Started Nov 2020; status: completed.
02
Drugs
dolutegravirlamivudine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04549467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04549467.